

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**Appendix 1. Search Strategy**

<b>Database</b>	<b>Strategy</b>
Medline (OVID) 1946–	<p>Long acting reversible contracept* OR LARC OR Intrauterine device* OR IUD*  OR (subdermal ADJ2 implant*) OR (sub-dermal ADJ2 implant*) OR  contraceptive implant* OR rod implant* OR single-rod implant* OR  levonorgestrel rod* OR Mirena OR Nexplanon OR Norplant OR Jadelle OR  ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon  AND  *Condoms/ut OR exp <b>Sexually Transmitted Diseases/pc OR HIV  Infections/pc OR exp Sexual Behavior/</b> OR Risk-Taking/ OR ((condom* ADJ5  use*) OR (condom* ADJ5 behavior*) OR sexually transmitted OR STIs OR STI  OR STD* OR chlamydia OR gonorrhea OR syphilis OR human  immunodeficiency virus* OR human immune deficiency virus* OR HIV* OR  AIDS OR acquired immunodeficiency syndrome OR acquired immune  deficiency syndrome OR (sex* adj3 (risk* OR work* OR behavior*)) OR risk  behavior* OR risky behavior* OR risk taking OR safe sex* OR unsafe sex* OR  unprotected sex* OR multiple partner*).ti,ab.  AND  (journal article or review or meta analysis).pt.  Limit 1990– ; Abstracts Available</p>
Embase (OVID) 1988–	<p>Long acting reversible contracept* OR LARC OR Intrauterine device* OR IUD*  OR (subdermal ADJ2 implant*) OR (sub-dermal ADJ2 implant*) OR  contraceptive implant* OR rod implant* OR single-rod implant* OR  levonorgestrel rod* OR Mirena OR Nexplanon OR Norplant OR Jadelle OR  ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon  AND  *Condom/ OR exp <b>Sexually Transmitted Disease/pc OR human  immunodeficiency virus infection/pc OR exp Sexual Behavior/</b> OR high risk  behavior/ OR ((condom* ADJ5 use*) OR (condom* ADJ5 behavior*) OR  sexually transmitted OR STIs OR STI OR STD* OR chlamydia OR gonorrhea  OR syphilis OR human immunodeficiency virus* OR human immune deficiency  virus* OR HIV* OR AIDS OR acquired immunodeficiency syndrome OR  acquired immune deficiency syndrome OR (sex* adj3 (risk* OR work* OR  behavior*)) OR risk behavior* OR risky behavior* OR risk taking OR safe sex*  OR unsafe sex* OR unprotected sex* OR multiple partner*).ti,ab.  AND  (article or review).pt.  Limit 1990– ; Abstracts Available</p>
PsycInfo (OVID) 1987–	<p>Long acting reversible contracept* OR LARC OR Intrauterine device* OR IUD*  OR (subdermal ADJ2 implant*) OR (sub-dermal ADJ2 implant*) OR  contraceptive implant* OR rod implant* OR single-rod implant* OR  levonorgestrel rod* OR Mirena OR Nexplanon OR Norplant OR Jadelle OR  ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon  AND  Condoms/ OR <b>Sexually Transmitted Diseases/ OR HIV/</b> OR exp sexual risk  taking/ OR ((condom* ADJ5 use*) OR (condom* ADJ5 behavior*) OR sexually</p>

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

	<p>transmitted OR STIs OR STI OR STD* OR chlamydia OR gonorrhea OR syphilis OR human immunodeficiency virus* OR human immune deficiency virus* OR HIV* OR AIDS OR acquired immunodeficiency syndrome OR acquired immune deficiency syndrome OR (sex* adj3 (risk* OR work* OR behavior*)) OR risk behavior* OR risky behavior* OR risk taking OR safe sex* OR unsafe sex* OR unprotected sex* OR multiple partner*).ti,ab.</p> <p>AND</p> <p>(peer reviewed journal).pt.</p> <p>Limit 1990– ; Abstracts Available</p>
Global Health (OVID) 1910–	<p>Long acting reversible contracept* OR LARC OR Intrauterine device* OR IUD* OR (subdermal ADJ2 implant*) OR (sub-dermal ADJ2 implant*) OR contraceptive implant* OR rod implant* OR single-rod implant* OR levonorgestrel rod* OR Mirena OR Nexplanon OR Norplant OR Jadelle OR ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon</p> <p>AND</p> <p>condoms/ OR <b>sexually transmitted diseases/ OR human immunodeficiency viruses/</b> OR risk behaviour.sh. OR ((condom* ADJ5 use*) OR (condom* ADJ5 behavior*) OR sexually transmitted OR STIs OR STI OR STD* OR chlamydia OR gonorrhea OR syphilis OR human immunodeficiency virus* OR human immune deficiency virus* OR HIV* OR AIDS OR acquired immunodeficiency syndrome OR acquired immune deficiency syndrome OR (sex* adj3 (risk* OR work* OR behavior*)) OR risk behavior* OR risky behavior* OR risk taking OR safe sex* OR unsafe sex* OR unprotected sex* OR multiple partner*).ti,ab.</p> <p>AND</p> <p>(journal article).pt.</p> <p>Limit 1990– ; Abstracts Available</p>
CINAHL (Ebsco)	<p>“Long acting reversible contracept*” OR LARC OR “Intrauterine device*” OR IUD* OR (subdermal N2 implant*) OR (sub-dermal N2 implant*) OR “contraceptive implant*” OR “rod implant*” OR “single-rod implant*” OR “levonorgestrel rod*” OR Mirena OR Nexplanon OR Norplant OR Jadelle OR ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon</p> <p>AND</p> <p>(MH “Condoms/UT”) OR (MH “Sexually Transmitted Diseases/PC”) <b>OR (MH “HIV Infections/PC”)</b> OR (MH “Risk Taking Behavior”) OR (TI ((condom* N5 use*) OR (condom* N5 behavior*) OR “sexually transmitted” OR STIs OR STI OR STD* OR chlamydia OR gonorrhea OR syphilis OR HIV* OR “human immunodeficiency virus” OR “human immune deficiency virus” OR AIDS OR “acquired immunodeficiency syndrome” OR “acquired immune deficiency syndrome” OR (sex* N3 (risk* OR work* OR behavior*)) OR “risky behavior” OR “risk taking” OR “unprotected sex” OR “multiple partner”)) OR (AB ((condom* N5 use*) OR (condom* N5 behavior*) OR “sexually transmitted” OR STIs OR STI OR STD* OR chlamydia OR gonorrhea OR syphilis OR HIV* OR “risk behavior” OR “sexual behavior” OR “sexual risk*” OR “risk taking” OR “safe sex” OR “unsafe sex” OR “human immunodeficiency virus” OR “human immune deficiency virus” OR AIDS OR “acquired immunodeficiency syndrome” OR “acquired immune deficiency syndrome” OR (sex* N3 (risk* OR</p>

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

	<p>work* OR behavior*)) OR “risky behavior” OR “risk taking” OR “unprotected sex” OR “multiple partner”))  AND  Limit 1990– ; Abstracts Available ; journal articles or reviews ; exclude Medline records</p>
Cochrane Library	<p>(“Long acting reversible contracept*” OR LARC OR “Intrauterine device*” OR IUD* OR (subdermal N2 implant*) OR (sub-dermal N2 implant*) OR “contraceptive implant*” OR “rod implant*” OR “single-rod implant*” OR “levonorgestrel rod*” OR Mirena OR Nexplanon OR Norplant OR Jadelle OR ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon):ti,ab  AND  [mh Condoms] OR [mh “Sexually Transmitted Diseases”] <b>OR [mh “HIV Infections”]</b> OR [mh “Risk-Taking”] OR ((condom* N5 use*) OR (condom* N5 behavior*) OR “sexually transmitted” OR STIs OR STI OR STD* OR chlamydia OR gonorrhea OR syphilis OR HIV* OR “risk behavior” OR “sexual behavior” OR “sexual risk*” OR “risk taking” OR “safe sex” OR “unsafe sex” OR “human immunodeficiency virus” OR “human immune deficiency virus” OR AIDS OR “acquired immunodeficiency syndrome” OR “acquired immune deficiency syndrome” OR (sex* N3 (risk* OR work* OR behavior*)) OR “risky behavior” OR “risk taking” OR “unprotected sex” OR “multiple partner”):ti,ab</p>
Scopus	<p>(TITLE-ABS-KEY(“Long acting reversible contracept*” OR LARC OR “Intrauterine device*” OR IUD* OR (subdermal W/2 implant*) OR (sub-dermal W/2 implant*) OR “contraceptive implant*” OR “rod implant*” OR “single-rod implant*” OR “levonorgestrel rod*” OR Mirena OR Nexplanon OR Norplant OR Jadelle OR ParaGard OR Liletta OR Skyla OR Kyleena OR Implanon))  AND (INDEXTERMS(Condoms OR “Sexually Transmitted Diseases” <b>OR “HIV Infections” OR “risk taking” OR “risk behavior”</b>) OR TITLE-ABS((condom* W/5 use*) OR (condom* W/5 behavior*) OR “sexually transmitted” OR STIs OR STI OR STD* OR chlamydia OR gonorrhea OR syphilis OR HIV* OR “risk behavior” OR “sexual behavior” OR “sexual risk*” OR “risk taking” OR “safe sex” OR “unsafe sex” OR “human immunodeficiency virus” OR “human immune deficiency virus” OR AIDS OR “acquired immunodeficiency syndrome” OR “acquired immune deficiency syndrome” OR (sex* W/3 (risk* OR work* OR behavior*)) OR “risky behavior” OR “risk taking” OR “unprotected sex” OR “multiple partner”)) AND PUBYEAR AFT 1989 AND NOT INDEX(medline)  Limit 1990– ; Abstracts Available; journal articles ; exclude Medline records</p>

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**Appendix 2.** Modified\* Newcastle-Ottawa Risk of Bias Scoring Guide

\*The assessment was based on modifications used in previous publications.<sup>32,33</sup> Compared with the original scale, we did not use separate assessments for cohort and case-control studies and added temporality of associations to ensure applicability for cross-sectional studies. We also added a specific criterion for sample size.

**(a) Representativeness of sample**

1: Representative of the average in the target population (census or random sampling, with >70% response rate)

0: Not representative or no description of the sampling strategy

**(b) Sample size (of highly and moderately effective contraceptive method users)**

1: Sample size is  $\geq 200$  or justified through a power analysis

0: Sample size is  $< 200$  and not justified

**(c) Temporality of associations**

1: Contraceptive type is measured at baseline and outcome(s) of interest is measured subsequent to baseline; For other sexual behaviors: Contraceptive type is measured at baseline and other sexual behavior(s) is measured subsequent to baseline or other sexual behavior(s) is measured at baseline and contraceptive type is measured

0: Contraceptive type and outcome of interest is measured at the same time

**(d) Comparability**

1: Account for relevant confounders (e.g., age, race/ethnicity, number of partners [particularly relevant for condom use outcome]) either through statistical adjustment or study design (e.g., randomization, matched case-control)

0: Relevant confounders not controlled for or a description of controls or randomization process not included

**(e) Ascertainment of contraceptive use**

1: Appropriate validated record for method (e.g., medical record for LARC) or structured interview with timeframe for use  $< 1$  year defined

0: Structured interview w/ timeframe for use  $\geq 1$  year, written self report or no description

**(f) Ascertainment of outcome(s)**

Note: A quality score will be assessed for each outcome so if a study examines multiple outcomes it will have multiple quality scores based on ascertainment of each outcome.

Condom use:

1: Study that uses a recommended condom use measure: (1) condom use at last sex, (2) consistent condom use, and (3) number of protected/ unprotected sex acts

0: Study that does not use a recommended condom use measure: (1) condom use at last sex, (2) consistent condom use, and (3) number of protected/ unprotected sex acts

Sexual risk behaviors:

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

1: Study uses self-report measure(s) with face validity as determined by 2 independent coders  
0: Study does not use self-report measure(s) with face validity (e.g., recall timeframe of past year) or sexual risk behavior measures are not described

HIV/STI incidence:

1: Laboratory diagnosis  
0: Self-report

Healthcare-related access:

1: Medical record/claims data  
0: Self-report

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**Appendix 3.** Modified Newcastle-Ottawa Scale Quality Assessment

<b>Outcome/Study</b>	<b>Representativeness of sample</b>	<b>Sample size quality</b>	<b>Ascertainment of contraception</b>	<b>Ascertainment of outcome</b>	<b>Temporality</b>	<b>Comparability</b>
<b>Condom use</b>						
Bastow et al., 2018	0	1	1	0	1	1
Berenson et al., 1995, 1997	0	0	1	1	1	0
Bernard et al., 2018	0	1	1	0	1	1
Cushman et al., 1998	0	1	1	0	1	1
Darney et al., 1999	0	0	1	0	1	0
Diaz et al., 1995	0	1	1	0	0	0
Eisenberg et al., 2012	1	1	1	0	0	1/0 <sup>a</sup>
El Ayadi et al., 2017	0	1	1	1	1	1
Gosavi et al., 2016	0	0	0	0	0	0
Kleinschmidt et al., 2003	1	1	0	1	0	0
Pazol et al., 2010	1	1	1	0	0	0
Schoenbaum et al., 2001	0	0	0	1	0	0
Steiner et al., 2016	1	1	0	1	0	1
Walsh-Buhi and Helmy, 2018	0	1	0	1	0	1
<b>Sexual risk behaviors</b>						
Avonts et al., 1990	0	0	0	0	1	0
Bastow et al., 2018	0	1	1	1	1	0
Brooks et al., 2017	0	1	0	0	0	0
Darney et al., 1999	0	0	1	0	1	0
Gavric-Lovrec and Takac, 2010	0	1	0	1	0	0
Kapiga et al., 1994	0	1	0	0	0	0
Steiner et al., 2016	1	1	0	1	0	1
Suhonen et al., 2004	0	0	1	0	1	1

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

Xu et al., 2019	1	1	1	1	0	0
STI-related services						
Rose et al., 2017	0	1	1	1	1	0
Steiner et al., 2018	1	1	1	0	0	1
STI infection						
Avonts et al., 1990	0	0	0	1	1	0
Berenson et al., 1997	0	0	1	1	1	0
Brahmbhatt et al., 2014	0	1	1	1	1	0
Ceruti et al., 1994	0	1	0	1	0	0
Cropsey et al., 2010	0	1	1	1	1	0
Feldblum et al., 2005	0	0	1	1	1	1
Guerreiro et al., 1998	0	1	1	1	0	0
Jenab et al., 2010	0	0	0	1	0	0
Lan et al., 2008	1	1	0	1	0	0
Porras et al., 2008	0	1	1	1	0	0
Rezk et al., 2017	0	1	1	1	1	0
Rose et al., 2017	0	1	1	1	1	0
Sharief, M. 1998	0	0	0	1	0	0
Shrikhande et al., 1995	0	0	0	1	0	0

<sup>a</sup>The comparison between LARC users and oral contraceptive users is adjusted; the comparison between LARC users and injectable, patch, ring users is unadjusted.

STI, sexually transmitted infection; LARC, long-acting reversible contraception.

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**Appendix 4. Study Characteristics**

<b>Study</b>	<b>Country</b>	<b>Study design</b>	<b>Age range or mean, years<sup>a</sup></b>	<b>Sample size,<sup>b</sup> n</b>	<b>Outcomes synthesized</b>
Avonts et al., 1990 <sup>37</sup>	Belgium	Prospective cohort	23.8 <sup>c</sup>	164	Chlamydia; Gonorrhea; Trichomoniasis; Other sexual behaviors
Bastow et al., 2018 <sup>38</sup>	U.S.	Prospective cohort	13–24	508	Condom use; Other sexual behaviors
Berenson et al., 1995, <sup>39</sup> 1997 <sup>25</sup>	U.S.	Case-control	11–18	70	Condom use; Chlamydia; Gonorrhea
Bernard et al., 2018 <sup>40</sup>	U.S.	Prospective cohort	14–45	6,744	Condom use
Brahmbhatt et al., 2014 <sup>41</sup>	Uganda	Prospective cohort	15–49	437	Trichomoniasis
Brooks et al., 2017 <sup>42</sup>	U.S.	Retrospective cohort	18–44	496	Other sexual behaviors
Ceruti et al., 1994 <sup>43</sup>	Italy	Cross-sectional	NR	530	Trichomoniasis
Cropsey et al., 2010 <sup>44</sup>	U.S.	Retrospective chart review	31.9	385	Chlamydia; Gonorrhea; Trichomoniasis
Cushman et al., 1998 <sup>45</sup>	U.S.	Prospective cohort	≥15	1,014	Condom use
Darney et al., 1999 <sup>23</sup>	U.S.	Prospective cohort	13–19	144	Condom use; Other sexual behaviors
Diaz et al. 1995 <sup>24</sup>	U.S.	Cross-sectional	18–50	221	Condom use
Eisenberg et al., 2012 <sup>46</sup>	U.S.	Cross-sectional	15–44	1,720	Condom use
El Ayadi et al., 2017 <sup>47</sup>	U.S.	Randomized clinical trial	18–25	765	Condom use
Feldblum et al., 2005 <sup>48</sup>	Brazil; Guatemala; Egypt; Vietnam	Randomized clinical trial	28.0 <sup>c</sup>	118	Chlamydia; Gonorrhea
Gavric-Lovrec and Takac, 2010 <sup>49</sup>	Slovenia	Retrospective cohort	35.7	1,000	Other sexual behaviors
Gosavi et al., 2016 <sup>50</sup>	Singapore	Cross-sectional	21–49	34	Condom use
Guerreiro et al., 1998 <sup>51</sup>	Portugal	Cross-sectional	NR	598	Chlamydia; Trichomoniasis
Jenab et al., 2010 <sup>52</sup>	Iran	Cross-sectional	19–60	13	Chlamydia
Kapiga et al., 1994 <sup>53</sup>	Tanzania	Cross-sectional	15–48	1,701	Other sexual behaviors
Kleinschmidt et al., 2003 <sup>54</sup>	South Africa	Cross-sectional	15–49	2,723	Condom use



**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

Lan et al., 2008 <sup>55</sup>	Vietnam	Cross-sectional	18–49	450	Chlamydia
Pazol et al., 2010 <sup>21</sup>	U.S.	Cross-sectional	15–44	1,552	Condom use
Porras et al., 2008 <sup>56</sup>	Costa Rica	Cross-sectional	18–25	3,734	Chlamydia
Rezk et al., 2017 <sup>57</sup>	Egypt	Prospective cohort	27.0 <sup>c</sup>	430	Trichomoniasis
Rose et al., 2017 <sup>58</sup>	New Zealand	Retrospective cohort	NR	5,013	STI-related services; Chlamydia
Schoenbaum et al., 2001 <sup>59</sup>	U.S.	Cross-sectional	18–55	118	Condom use
Sharief M, 1998 <sup>60</sup>	Iraq	Cross-sectional	15–44	149	Gonorrhea; Trichomoniasis
Shrikhande et al., 1995 <sup>61</sup>	India	Cross-sectional	27.8 <sup>c</sup>	146	Chlamydia
Steiner et al., 2016 <sup>22</sup>	U.S.	Cross-sectional	9th–12th grade	619	Condom use; Other sexual behaviors
Steiner et al., 2018 <sup>62</sup>	U.S.	Cross-sectional	15–24	1,048	STI-related services
Suhonen et al., 2004 <sup>63</sup>	Sweden; Finland	Randomized clinical trial	18–25	147	Other sexual behaviors
Walsh-Buhi and Helmy, 2018 <sup>7</sup>	U.S.	Cross-sectional	18–24	5,259	Condom use
Xu et al., 2011 <sup>64</sup>	U.S.	Cross-sectional	15–44	1,698	Other sexual behaviors

<sup>a</sup>We extracted the overall age range from the sample description or if not available, the age range from the eligibility criteria. If age range was not provided, we present the overall mean age of the sample, if available.

<sup>b</sup>Number of LARC and moderately effective method users. For prospective studies, number at follow-up and if available, number of continuing users at final follow-up.


<sup>c</sup>Stratified mean age was reported. We present overall mean by calculating a weighted average.

NR, not reported; STI, sexually transmitted infection; LARC, long-acting reversible contraception.

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**Appendix 5. Forest Plots**


**a. Condom Use: LARC Users vs. Oral Contraceptive Users**



<sup>a</sup>Raw numbers were extracted or calculated from percentages and sample sizes.

<sup>b</sup>Study reported 99% confidence intervals; 95% confidence intervals are reported here.

**b. Condom Use: LARC Users vs. Injectable, Patch, or Ring Users**




<sup>a</sup>Raw numbers were extracted or calculated from percentages and sample sizes.

<sup>b</sup>Study compared injectable, patch, ring to LARC so inverse is presented here.


<sup>c</sup>Study reported 99% confidence intervals; 95% confidence intervals are reported here.

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**c. Condom Use: LARC Users vs. Moderately Effective Contraceptive Methods Users**




**d. CT/GC: LARC Users vs. Oral Contraceptive Users<sup>a</sup>**



<sup>a</sup>For all studies, raw numbers were extracted or calculated from percentages and sample sizes.


**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**e. CT/GC: LARC Users vs. Injectable Users<sup>a</sup>**



<sup>a</sup>For all studies, raw numbers were extracted or calculated from percentages and sample sizes.


**f. CT: LARC Users vs. Moderately Effective Contraceptive Method Users<sup>a</sup>**



<sup>a</sup>For all studies, raw numbers were extracted or calculated from percentages and sample sizes.

**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**g. Trich: LARC Users vs. Oral Contraceptive Users<sup>a</sup>**




<sup>a</sup>For all studies, raw numbers were extracted or calculated from percentages and sample sizes.


**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**Appendix 6. Funnel Plots**

**a. Condom use: LARC Users vs. Oral Contraceptive Users**




**b. Condom use: LARC Users vs. Injectable, Patch or Ring Users**




**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**c. Condom use: LARC Users vs. Moderately Effective Method Users**




**d. CT/GC: LARC Users vs. Oral Contraceptive Users**




**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**e. CT/GC: LARC Users vs. Injectable Users**



**f. CT: LARC Users vs. Moderately Effective Method Users**





**Appendix**  
**Long-Acting Reversible Contraception, Condom Use, and Sexually Transmitted Infections:**  
**A Systematic Review and Meta-analysis**  
**Steiner et al.**

**g. Trichomoniasis: LARC Users vs. Oral Contraceptive Users**

